Protein / target
Glucagon-like peptide 1 receptor
Protein at a glance
Biological role
Glucagon-like peptide 1 receptor activity
Primary system
Cardiovascular system
Strongest disease association
diabetes mellitus
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
7 approved · 10 in clinical development
Research activity
Extensively researched
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
G protein-coupled receptor for glucagon-like peptide 1 (GLP-1) (PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449, PubMed:7517895, PubMed:8216285, PubMed:8405712). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels (PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449, PubMed:7517895, PubMed:8216285, PubMed:8405712). Plays a role in regulating insulin secretion in response to GLP-1 (By similarity)
Subcellular location
Domains and Gene Ontology detail (14)Hide
Gene Ontology
- Cmembrane
- Cplasma membrane
- Fglucagon receptor activity
- Fglucagon-like peptide 1 receptor activity
- Fpeptide hormone binding
- Ftransmembrane signaling receptor activity
- Pactivation of adenylate cyclase activity
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
- Pcell surface receptor signaling pathway
- Plearning or memory
- Ppositive regulation of blood pressure
- Ppositive regulation of cytosolic calcium ion concentration
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
G protein-coupled signalling
- ·G protein-coupled receptor for glucagon-like peptide 1 (GLP-1) (PubMed:19861722, PubMed:…
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Glucagon-like peptide 1 receptor agonist
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, type 2 diabetes mellitus, type 2 diabetes mellitus
Glucagon-like peptide 1 receptor agonist
Appears in clinical studies involving type 2 diabetes mellitus, Hypertension, Obesity, diabetes mellitus
Glucagon-like peptide 1 receptor agonist
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, type 2 diabetes mellitus, type 2 diabetes mellitus
Glucagon-like peptide 1 receptor antagonist
Glucagon-like peptide 1 receptor agonist
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, type 2 diabetes mellitus, type 2 diabetes mellitus
Glucagon-like peptide 1 receptor agonist
Appears in clinical studies involving type 2 diabetes mellitus, diabetes mellitus, type 2 diabetes mellitus, type 2 diabetes mellitus
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Show all associationsHide all associations
Open Targets ranks 1,187 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 17 total
type 2 diabetes mellitus · type 2 diabetes mellitus · obesity disorder
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
type 2 diabetes mellitus · type 2 diabetes mellitus · chronic kidney disease
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
Alzheimer disease · Parkinson disease · Parkinson disease
type 2 diabetes mellitus · Hypertension · Obesity
Obesity · cardiovascular disorder · obesity disorder
type 1 diabetes mellitus · type 2 diabetes mellitus · type 2 diabetes mellitus
type 2 diabetes mellitus
type 2 diabetes mellitus · diabetes mellitus · type 2 diabetes mellitus
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 5 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Industry developmentAI helps Stanford scientists discover “natural Ozempic” without the usual side effects
- Industry developmentAI helps Stanford scientists discover “natural Ozempic” without the usual side effects
- Industry developmentThe billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
- Industry developmentOzempic and Mounjaro linked to a surprising hair loss risk
- Trial status changed
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- Industry developmentPopular weight-loss drugs Ozempic and Wegovy may slow biological aging
- Industry developmentThe Ozempic and Wegovy mistake sending thousands to poison control
- Clinical trial activityNew weight loss pill beats oral Ozempic in major trial
- Regulatory approval
Approval: LIRAGLUTIDE (ANDA212972)
- Industry developmentOzempic changed obesity treatment, but experts say the real revolution is next
- Industry developmentOzempic changed obesity treatment, but experts say the real revolution is next
- Supplemental approval
Supplemental approval: SEMAGLUTIDE (NDA215256)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.